Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2006-11-13
2010-06-08
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S005000
Reexamination Certificate
active
07732166
ABSTRACT:
Embodiments of the invention provide methods, assays, and kits for detecting HPV infection and HPV associated epithelial cell abnormalities, most notably those associated with pre-malignant and malignant epithelial cell lesions. Detection of HPV DNAs, genomes, and/or oncoproteins by nucleic acid hybridization assays and immunological assays can be used in early clinical screening for HPV infection and diagnosis for cervical cancer. The polypeptides, recombinant proteins, antibodies, nucleic acids, and various detection methods thereof are particularly useful for diagnosing carcinomas of the uterine cervix and those at risk of developing cervical cancer.
REFERENCES:
patent: 3633999 (1972-01-01), Buckles
patent: 4511220 (1985-04-01), Scully
patent: 4619508 (1986-10-01), Shibuya et al.
patent: 4744615 (1988-05-01), Fan et al.
patent: 4851978 (1989-07-01), Ichihara
patent: 5061025 (1991-10-01), Debesis
patent: 5109465 (1992-04-01), Klopotek
patent: 5224200 (1993-06-01), Rasmussen et al.
patent: 5233460 (1993-08-01), Partlo et al.
patent: 5307207 (1994-04-01), Ichihara
patent: 5315427 (1994-05-01), Rauch et al.
patent: 5328785 (1994-07-01), Smith et al.
patent: 5357365 (1994-10-01), Ipposhi et al.
patent: 5401627 (1995-03-01), Dillner et al.
patent: 5415995 (1995-05-01), Schoolnik et al.
patent: 5453814 (1995-09-01), Aiyer
patent: 5561081 (1996-10-01), Takenouchi et al.
patent: 5610733 (1997-03-01), Feldman et al.
patent: 5621529 (1997-04-01), Gordon et al.
patent: 5629161 (1997-05-01), Muller et al.
patent: 5662410 (1997-09-01), Suganuma
patent: 5665535 (1997-09-01), Orth et al.
patent: 5679509 (1997-10-01), Wheeler et al.
patent: 5699191 (1997-12-01), Fork
patent: 5754278 (1998-05-01), Kurtz
patent: 5876723 (1999-03-01), Cole et al.
patent: 5888888 (1999-03-01), Talwar et al.
patent: 5914389 (1999-06-01), Huibregtse et al.
patent: 6013262 (2000-01-01), Frazer et al.
patent: 6228578 (2001-05-01), Impraim et al.
patent: 6355424 (2002-03-01), Lorinez et al.
patent: 6420106 (2002-07-01), Gyllensten et al.
patent: 6524825 (2003-02-01), Mizzen et al.
patent: 6743593 (2004-06-01), Hu
patent: 6827933 (2004-12-01), Orth et al.
patent: 6884786 (2005-04-01), Kieny et al.
patent: 6890514 (2005-05-01), Mathur et al.
patent: 6900035 (2005-05-01), Mizzen et al.
patent: 6933123 (2005-08-01), Hu et al.
patent: 2005/0037017 (2005-02-01), Mizzen et al.
patent: 2005/0037342 (2005-02-01), Mathur et al.
patent: 2005/0142541 (2005-06-01), Lu et al.
patent: 2005/0147621 (2005-07-01), Higgins et al.
patent: 2005/0255460 (2005-11-01), Lu et al.
patent: 2005/0255468 (2005-11-01), Ridder et al.
patent: 2005/0260566 (2005-11-01), Fischer et al.
patent: 2006/0029943 (2006-02-01), Hermonat et al.
patent: 2006/0039919 (2006-02-01), Chang et al.
patent: 2006/0121516 (2006-06-01), Norman et al.
patent: 2006/0153864 (2006-07-01), Gissmann et al.
patent: 2006/0172285 (2006-08-01), Patterson
Christensen et al, Virology, 1996, vol. 223, pp. 174-184.
Nomine et al, Protein Engineering, 2001, vol. 14, No. 4, pp. 297-305.
Bjorndal et al, Protein Expression and Purification, 203, vol. 31, pp. 47-55.
Miraka et al, Protein Expression and Purification, 2006, vol. 48, 281-291.
Bosch, et al 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 87:796-802.
Doeberitz, Magnus Von Knebel “New Molecular tools for efficient screening of cervical cancer”, Disease Markers 17 (2001) 123-128.
Fisher, et al. “The Association of Human Papillomavirus Type 16 E6 and E7 Antibodies with stage of Cervical Cancer”, Gynecologic Oncology 61, 73-78 (1996) Article No. 0099.
Guimaraes, et al. 2005. “Immunohistochemical expression of p16INK4a and bcl-2 according to HPV type and to the progression of cervical squamous intraepithelial lesions”. J Histochem Cytochem. 53: 509-16).
Hagensee, et al. “Detection of Cervical Antibodies to Human Papillomavirus Type 16 (HPV-16) Capsid Antigens in Relation to Detection of HPV-16 DNA and Cervcal Lesions”, The Jourrnal of Infectious Diseases 2000; 181:1234-9.
Kiviat, et al. 1993. Specific human papillomavirus types as the causal agents of most cervical intraepithelial neoplasia: implications for current views and treatment. J Natl Cancer Inst 85: 934-35.
Koutsky, et al. 1992. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl J Med 327:1272-1278. Abstract Only.
Kuroda, et al. 2005. The human papillomavirus E6 and E7 inducible oncogene, hWAPL, exhibits potential as a therapeutic target. Br J Cancer 92:290-3.
Li, et al. 2005. Regulation of apoptosis by papillomavirus E6 oncogene. World J Gastroenterol 11:931-37.
Longworth, et al., 2004. Pathogenesis of human papillomavirus in differentiating epithelia. Microbiol Mol Biol Rev 68: 362-72.
Madrigal, et al. 1997. In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma. Gynecol Oncol 64: 18-25.
Meschede, et al. “Antibodies agains Early Proteins of Human Papillomaviruses as Diagnostic Markers for Invasive Cervical Cancer” Journal of Clinical Microbiology Feb 1998, pp. 475-480.
Munoz, et al. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl J Med 348:518-27.
Park, et al. 1995. Molecular biology of cervical cancer and its precursors. Cancer 76: 1902-13.
Park, et al. “HPV-16-Related Proteins as the Serolgic Markers in Cervical Neoplasia”, Gynecologic Oncology 69, 47-55 (1998).
Parkin, et al. 1993. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594-606.
Sehr, et al. “A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology” Journal of Immunological Methods 253 (2001) 153-162.
Solomon, et al. 2002. The 2001 Bethesda Systems. Terminology for reporting results of cervical cytology. JAMA 287:2114-19.
Studentsov, et al. “Polymer-Based Enzyme-Linked Immunosorbent Assay Using Human Papillomavirus Type 16 (HPV16) Virus-Like Particles Detects HPV16 Clade-Specific Serologic Responses”, Journal of Clinical Microbiology Jul. 2003 pp. 2827-2834.
Sun, et al., “Comparison of Peptide Enzyme-Linked Immunosorbent Assay and Radioimmunoprecipitation Assay with in Vitro-Translated Proteins for Detection of Serum Antibodies to Human Papillomavirus Type 16 E6 and #7 Proteins” Journal of Clinical Microbiology Sep. 1994 pp. 2216-2230.
Tjiong, et al. “Antibodies agains Human Papillomavirus Type 16 and 18 E6 and E7 Proteins in Cervicovaginal Washings and Serum of Patients with Cervical Neoplasia” Viral Imjmunolgy vol. 14, No. 4, 2001 pp. 415-424.
Veress, et al. “Human Papillomavirus DNA and Anti-HPV Secretory IgA Antibodies in Cytologically Normal Cervical Specimens” Journal of Medical Virology 43:201-207 (1994).
Viscidi, et al. 1993. Serologic response in human papillomavirus-associated invasive cervical cancer. Int. J. Cancer 55:780-784.
Walboomers, et al. “Human Papillomavirus is a Necessary Cause of Invasive Cervical Cancer Worldwide”, Jouranl of Pathology 189:12-19 (1999).
Wang, et al. “Cervical Mucus Antibodies against Human Papillomavirus Type 16, 18, and 33 Capsids in Relation to Presence of Viral DNA” Journal of Clinical Microbiology Dec. 1996 pp. 3056-3062.
Zumbach, et al “Antibodies Against Oncoproteins E6 and E7 of Human Papillomavirus Types 16 and 18 in Cervical-Carcinoma Patents from Russia”, Int. J. Cancer 85, 313-318 (2000) [Publication of the International Union Against Cancer].
International Search Report dated Jul. 18, 2007.
Berumen, et al. 2001 Asian-American Variants of Human Papillomavirus 16 and Risk for Cervical Cancer: a CaseControl Study Journal of the National Cancer Institute, vol. 93, No. 17.
Bleul, et al., “Human Papillomavirus Type 18 E6 and E7 Antibodies in Human Sera: Increased Anti-E7 Prevalence in Cervical Cancer Patients” Journal of Clinical Microbiology, Aug. 1991 p
Fenwick & West LLP
OncoHealth Corporation
Salimi Ali R.
LandOfFree
Detection method for human pappilomavirus (HPV) and its... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detection method for human pappilomavirus (HPV) and its..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection method for human pappilomavirus (HPV) and its... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4202875